Download - Alkylating agents by Dr.Neenu Thomas
![Page 1: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/1.jpg)
Alkylating Agents
Dr.Neenu Thomas1st Yr PG, Dept. Of Radiotherapy
![Page 2: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/2.jpg)
HISTORY• Mechlorethamine-
first alkylating agent-1942
• Analogue of Sulphur mustard gas
• Weapon in first world war-1917
![Page 3: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/3.jpg)
Alkylating Agents
Nitrogen Mustards
CarmustineLomustineStreptozotocin
BusulfanCyclophosphamideIfosfamideMelphalanChlorambucilMechlorethamine
AziridinesAlkyl
Sulfonates
Nitrosoureas Triazenes
DacarbazineTemozolomide
Thio TEPA
![Page 4: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/4.jpg)
![Page 5: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/5.jpg)
Mechanism of DNA alkylation by a reactive nitrogen mustard molecule and formation of
interstrand cross-link
MOA
![Page 6: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/6.jpg)
Monofunctional adducts and 1,2- and 1,3-interstrand and intrastrand cross-links induced
by DNA interactive agents. X = antitumour agent.
MOA
![Page 7: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/7.jpg)
CYCLOPHOSPHAMIDE
![Page 8: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/8.jpg)
• Inactive in parent form • Activated by liver cyt-
p450 to cytotoxic metabolites PM & acrolein
• DNA adduct
MOA
Mechanism of Action
![Page 9: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/9.jpg)
PHARMACOKINETICS• ROA- iv in Dextrose 5% or
NaCl 0.9 %, Oral• Absorption bioavailability
90%• Vol of Dist-0.6L/Kg• Distribution-including brain
& csf,also in milk & saliva• Protein binding- <20%
Cyclophosphamide & Ifosfamide
![Page 10: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/10.jpg)
PHARMACOKINETICS• Metabolism- Prodrug
activation by Cyt-p450 active forms are 4 hydroxycyclophosphamide phosphoramide mustard & acrolein
• Elimination-t1/2- 4-6 hours parent drug & metabolites exclusively in urine
Cyclophosphamide & Ifosfamide
![Page 11: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/11.jpg)
Indications• Breast Cancer• Ovarian Cancer• Sarcoma• NHL• High dose regimen-in bone
marrow transplantation and for other autoimmune disorders
![Page 12: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/12.jpg)
Dosage range• Breast cancer 100mg/m2 po
days 1-14 every 28 days,iv 600mg/m2 every 21 days AC or CMF
• NHL 400-600 mg/m2 iv every 21 days CVP,750mg/m2 every 21 days CHOP
• High dose BMT 60mg/kg iv for 2 days
![Page 13: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/13.jpg)
DRUG INTERACTION • Inhibit Activation of CP
– Antifungal Agents– Allopurinol– Chlorpromazine– Thiotepa
• Enzyme inducers– Steroids– Anticonvulsants
• Cp increase the effect Anticoagulants • Dec. the plasma levels of digoxin• Inc. the risk of doxorubicin induced cardiotoxicity
![Page 14: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/14.jpg)
• Caution in patients with abnl renal fuction
• Encourage fluid intake 2-3l/day
• Empty bladder several times daily
Special consideration
![Page 15: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/15.jpg)
• Myelosuppression- dose limiting mainly leukopenia 7-14 days
• Nausea & vomiting 2-4 hrs• Alopecia 2-3 wks • Amenorrhoea with ovarian failure • Cardiotoxicity• Sec malig AML & bladder cancer• SIADH
Toxicity
![Page 16: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/16.jpg)
TOXICITY
![Page 17: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/17.jpg)
• Hemorrhagic cystitis- Excretion of Acrolein– Rx
• Adequate hydration• Continuous irrigation of bladder with
MESNA (2mercaptoethanesulfonate)• Frequent bladder emptying
– MESNA• Free sulfhydryl• Divided doses every 4 hrs- 60% of
alkylating agents
TOXICITY
![Page 18: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/18.jpg)
IFOSFAMIDE
![Page 19: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/19.jpg)
• ROA- oral or iv • Absorption- bioavailability
100%• Distribution- Widely
distributed• Protein binding 20%• Metabolism in liver • Elimination- 50-70% excreted
in urine • T1/2- 3 -10hrs
PHARMACOKINETICS
![Page 20: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/20.jpg)
Indication • Osteogenic sarcoma • Ewing sarcoma• HL &NHL • Non small cell & small cell lung
cancer• Bladder cancer • Recurrent germ cell tumors
![Page 21: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/21.jpg)
Drug Interaction • Anticonvulsants, cimetidine &
allopurinol increase the metabolism –enhanced toxicity
• Cisplatin increases renal toxicity • Enhances anticoagulant effects
of warfarin
![Page 22: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/22.jpg)
• Caution in patients with abnl renal function
• Uroprotection with mesna & hydration
• Monitor coagulation parameters
Special consideration
![Page 23: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/23.jpg)
Toxicity• Myelosuppression• Bladder toxicity dose limiting • Alopecia >80 %• Amenorrhoea oligospermia
![Page 24: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/24.jpg)
• High dose ifosfamide– Neurotoxicity
• Seizures, altered mental status,CN palsies, coma
• Painful and acute exacerbation of peripheral sensory neuropathies and motor dysfunction of distal extremities
• N-linked Chloroethyl Chloro Acetaldehyde
TOXICITY
OxidationN-Deethylation
Recommendations High risk - S.Cr>1.5mg or S.Albumin <3g/dl or both Multiple day regimens reduce risk Monitor-early signs(irritability,anxiety,hallucinations) Terminate ifosfamide Palliative therapy
![Page 25: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/25.jpg)
Mechlorethamine
![Page 26: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/26.jpg)
• Absorption- not orally bioavailable
• Metabolism- rapid hydrolysis in plasma
• Elimination- >50% in urine
• T ½- 15-20 min
PHARMACOKINETICS
![Page 27: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/27.jpg)
Indication • HL• NHL • Cutaneous T cell lymphoma • Intrapleural intrapericardial
intraperitoneal treatment of metastatic disease
![Page 28: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/28.jpg)
• HL 6 mg/m2 iv D1 &D8 every 28 days MOPP regimen
• Cutaneous 10mg in 60ml sterile water
• Intracavitary use 0.2 0.4 mg/kg
Dosage range
![Page 29: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/29.jpg)
• Sod thiosulfate inactivates
Drug Interaction
![Page 30: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/30.jpg)
• Potent vesicant • Inflammation &
necrosis pvt by instillation of 2.6 % sod thiosulfate solution
Special consideration
![Page 31: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/31.jpg)
Melphalan
Phenylalanine
![Page 32: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/32.jpg)
Mono & Bifunctional DNA Adduct
Mechanism of Action
Melphalan
![Page 33: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/33.jpg)
PHARMACOKINETICS• ROA- Oral & iv• Absorption-oral
absorption poor Bioavail 60% Food Reduces
• Vol of Dist- 0.5L/Kg• Distribution-Protein
binding >50 %Melphalan
![Page 34: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/34.jpg)
PHARMACOKINETICS
• Elimination – via Hydrolysis of chloro ethyl sidechains to mono and dihydroxy forms
• 25-30% in urine • 13-40 min (iv)
Melphalan
![Page 35: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/35.jpg)
• Multiple Myeloma• Ovarian cancer• Myeloablative therapy
– Bone marrow transplant
CLINICAL USE
Melphalan
![Page 36: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/36.jpg)
• Multiple myeloma -9mg/m2 iv D1-D4 every 4 weeks melphalan prednisone regimen
• Transplant 140mg/m2 single agent
Dosage range
![Page 37: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/37.jpg)
DRUG INTERACTION • Cimetidine
– 30% reduction in Melphalan Absorption
– Steroids enhance antitumor activity
– Cyclosporine enhance renal toxicity
Melphalan
![Page 38: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/38.jpg)
Chlorambucil
Aromatic Mustard
![Page 39: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/39.jpg)
PHARMACOKINETICS• ROA- Oral bioavailability
75%• Absorption- Food
Reduces• Distribution-Protein
binding >98 %• CNS Penetration- low
con in CSFChlorambucil
![Page 40: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/40.jpg)
PHARMACOKINETICS• Metabolism-liver cyt
p450 Phenyl acetic acid
• Elimination – 60% of drug metabolites eliminated in urine
• T1/2 1.5-2.5 hrsChlorambucil
![Page 41: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/41.jpg)
• CLL• NHL• HL
Indication
![Page 42: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/42.jpg)
• CLL 0.1 0.2mg/kg Po daily 3-6 wks-initiation
• 2-4mg po daily maintenance
Dosage range
![Page 43: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/43.jpg)
• Anticonvuslants increased formation of toxic metabolites
Drug Interaction
![Page 44: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/44.jpg)
Special consideration• Caution when
combined with allopurinol –drug induced hyperuricemia
• Closely monitor CBCs• Discontinued if
generalised skin rash develops-EM,TEN,SJS
![Page 45: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/45.jpg)
• Myelosupression• Nausea & vomiting • Hyperuricemia• Pulmonary fibrosis & pneumonitis• Skin rash urticaria• Amenorrhoea ,oligospermia • Sec malig
Toxicity
![Page 46: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/46.jpg)
Neurotoxicity–Phenylacetic acid–Oxidative N
dechloroethylation
TOXICITY
Chlorambucil
![Page 47: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/47.jpg)
Thiotepa
Thiotepa
![Page 48: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/48.jpg)
PHARMACOKINETICS• ROA- iv intravesical
Absorption oral incomplete
• Protein binding- <10%• CNS penetration-
CSFcon equivalent to plasma
• Distribution- 0.7L/KgThiotepa
![Page 49: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/49.jpg)
PHARMACOKINETICS
• Metabolism– Thiotepa TEPA– inactivation by CYP2B
• Elimination- 60%in urine – t1/2 < 2hr
Thiotepa
![Page 50: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/50.jpg)
• Breast cancer• Ovarian cancer• HL• NHL
Indication
![Page 51: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/51.jpg)
• 10-20mg/m2 iv every 3-4 weeks
• Intravesical instillation 60mg in 60ml sterile water weekly upto 4 weeks
Dosage range
![Page 52: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/52.jpg)
• Monitor cbc after intravesical adm –bone marrow depression from systemically absorbed drug
• Resuscitation equipment should be available-hypersensitivity
• Caution about the chance of skin changes urticaria, bronzing, flaking
Special consideration
![Page 53: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/53.jpg)
Busulphan
Busulphan
![Page 54: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/54.jpg)
PHARMACOKINETICS• Highly variable
–Age –Circadian variation–Disease type
• ROA- Oral • Absorption- excellent
bioavailabilityBusulphan
![Page 55: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/55.jpg)
PHARMACOKINETICS• CNS Penetration- Enter
Easily• Vol of Dist- 27+/- 11L/m2
• Metabolism- By liver cyt p450
• Elimination-t1/2 2.5hrs• Higher clearance rate in
evening in young– Faster in Children– Less rapidly in leukemic
patients Busulphan
![Page 56: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/56.jpg)
CLINICAL USE
• CML• Myeloablative
treatment- prior to BMT
Busulphan
![Page 57: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/57.jpg)
• CML remission induction 4-8mg/day po
• Maintenance dose 1-3mg/day po
• Transplant 4mg/day iv 4 days
Dosage range
![Page 58: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/58.jpg)
• Pretreatment with Anti convulsants increase rate of elimination by 20%
• Concurrent treatment with CP increases clearance
• Acetaminophen& itraconazole decrease metabolism enhanced toxicity
Busulphan
Drug Interaction
![Page 59: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/59.jpg)
Special consideration• Monitor patients
for pulmonary symptoms
• Ingestion on an empty stomach decrease the risk of nausea
![Page 60: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/60.jpg)
Toxicity• Myelosuppression• Nausea and vomiting >80%• Mucositis• Impotence, male
sterility ,amenorrhoea• Interstitial pulmonary fibrosis
busulfan lung may occur 1-10 yrs after therapy
• Hepatovenoocclusive disease >16mg/day
![Page 61: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/61.jpg)
Nitrosourea
Nitrosourea
![Page 62: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/62.jpg)
Carmustin (BiCNU)
Nitrosourea
![Page 63: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/63.jpg)
By alkylation of DNA and
possibly by carbamoylation
of protein
Mechanism of Action
Nitrosourea
![Page 64: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/64.jpg)
PHARMACOKINETICS• ROA- iv• Absorption- not absorbed
orally• Distribution lipid soluble
drug cross BBB >50%in plasma– Metabolism- Spontaneous
decomposition to chloroethyl carbonium ion
– Isocyanate may also form
Nitrosourea
![Page 65: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/65.jpg)
PHARMACOKINETICS
• Vol of Dist- 3-5 L/kg• Elimination-60-70% in
urine – mostly as metabolites– t1/2 0.4-4.3 h
Nitrosourea
![Page 66: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/66.jpg)
CLINICAL USE• Brain tumour-
GBM,glioma• Multiple
Myeloma• Hodgkins
Lymphoma,NHLNitrosourea
![Page 67: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/67.jpg)
• 200mg/m2 iv every 6 weeks
• Implantable BCNU impregnated wafers at the surgical resection
Dosage range
![Page 68: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/68.jpg)
• Cimetidine & amphotericin B enhances toxicity
• decrease the plasma level of Digoxin & phenytoin
Drug Interaction
![Page 69: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/69.jpg)
• Administer slowly over a period of 1-2 hrs to avoid intense pain & burning
• Pfts should be obtained at baseline
Special consideration
![Page 70: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/70.jpg)
Toxicity• Facial flushing & burning
sensation at the iv site• Hepatotoxicity with elevated
LFT 90% within 1 week ,hepatovenoocclusive d/s 5-20%
• Pulmonary toxicity at cumulative dose >1400
![Page 71: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/71.jpg)
Lomustin (CCNU)
Nitrosourea
![Page 72: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/72.jpg)
• Absorption- completely orally • Distribution- Lipid soluble
drug with broad tissue distribution
• Cross BBB and csf con 15-30 %of plasma levels
• Metabolism- in liver • Elimination- 50% in urine • T1/2- 72 hrs
PHARMACOKINETICS
![Page 73: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/73.jpg)
•Brain tumor•HL•NHL
Indication
![Page 74: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/74.jpg)
130mg/m2 po every 6 weeks
Dosage range
![Page 75: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/75.jpg)
• PFTs monitored periodically
• Administer drug on empty stomach
Special consideration
![Page 76: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/76.jpg)
• Decreased cellular uptake of drug• Decreased expression of drug
activating enzymes of the liver p450 system
• Increased expression of sulfhydryl proteins including gluthathione and asso enzymes
• Increased expression of aldehyde dehydrogenase resulting in enhanced enzymatic detoxification of drug
• Enhanced activity of dna repair enzymes
Mechanism of Resistance
![Page 77: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/77.jpg)
Dacarbazine
Nonclassic alkylating agent
![Page 78: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/78.jpg)
• Methylates nucleic acids and inhibits DNA RNA & protein syn
Mechanism of Action
![Page 79: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/79.jpg)
Mechanism of Resistance• Increased
activity of DNA repair enzymes O6alkyl guanine DNA alkyl transferase (AGAT)
![Page 80: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/80.jpg)
• ROA- iv• Absorption- slow & variable • Distribution- widely
distributed • Protein binding- 20%• Metabolism- in liver to MTIC
AIC• Elimination- 40 -60%
unchanged in urine• t1/2- 5 hrs
PHARMACOKINETICS
![Page 81: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/81.jpg)
• Metastatic malignant melanoma
• HL • Sarcoma• Neuroblastoma
Indication
![Page 82: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/82.jpg)
• HL 375mg/m2 iv D1 D15 every 28 days ABVD
Dosage range
![Page 83: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/83.jpg)
• Heparin lignocaine hydrocortisone incompatible with dacarbazine
• Anticonvulsants decrease the efficacy
Drug Interaction
![Page 84: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/84.jpg)
• Potent vesicant• Use of
aggressive antiemetics
• Avoid sunexposure
Special consideration
![Page 85: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/85.jpg)
Toxicity• Flu like syndrome• CNS toxicity paresthesia
neuropathies, ataxia,seizures
• Photosensitivity• Teratogenic
![Page 86: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/86.jpg)
Temozolomide
![Page 87: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/87.jpg)
TemozolomideSpontaneously releases the cytotoxic species 3-methyl-(triazen-1-yl) imidazole-4-carboxamide(MTIC)
DacarbazineRequires metabolic activation mediated by microsomal enzymes
CH3
![Page 88: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/88.jpg)
• Imidazotetrazine analog• Methylates guanine
residues(N7,O6) in DNA and inhibits DNA,RNA,protein syn
• Cytotoxicity-formation of O6 methyl guanine adducts
Mechanism of Action
![Page 89: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/89.jpg)
Mechanism of Resistance• Increased
activity of DNA repair enzymes O6alkyl guanine DNA alkyl transferase (AGAT)
![Page 90: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/90.jpg)
PHARMACOKINETICS• ROA- Oral,iv• Absorption-
–oral bioavailability 100%
–Food reduces • Peak con- <1 h
Nitrosourea
![Page 91: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/91.jpg)
PHARMACOKINETICS• CNS Penetration- High, CSF
con 30-40% Selective distribution over tumour in brain
• Metabolism- MTIC &AIC• Vol of Dist- 3-5 L/m2
• Elimination-– Majority in urine 40-50%
• t1/2- 1.8hNitrosourea
![Page 92: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/92.jpg)
• 150mg/m2 po daily for 5 days -28 days
• 75mg/m2 po daily for 42 days with RT- GBM
Dosage range
![Page 93: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/93.jpg)
CLINICAL USE
• Glioma• Astrocytoma• Melanoma
Busulphan
![Page 94: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/94.jpg)
DRUG INTERACTION Toxicity increases in prior exposure to nitrosureas
![Page 95: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/95.jpg)
• Moderately emetogenic agent.
• Avoid sun exposure after Rx
• Caution in elderly patients
Special consideration
![Page 96: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/96.jpg)
Toxicity• Myelosupression-Dose
limiting toxicity• Photosensitivity• Teratogenic
![Page 97: Alkylating agents by Dr.Neenu Thomas](https://reader035.vdocument.in/reader035/viewer/2022062306/58777cc01a28abc85f8b4ccb/html5/thumbnails/97.jpg)